Jun Terauchi
Chief Scientific Officer Metagen Therapeutics
Seminars
Tuesday 10th November 2026
Leveraging Japanese Donor FMT Clinical Data to Decode Microbiome Dynamics & Advance Patient-Donor Matching Strategies
4:30 pm
- Presenting clinical results from Metagen’s phase one two IBD program to demonstrate how Japanese donor microbiota composition drives therapeutic efficacy in ulcerative colitis
- Analyzing gut microbiota dynamics before and after FMT to identify essential species driving microbiome modification and inform more targeted therapeutic delivery strategies
- Applying patient-donor matching strategies and microbiome analytical insights to address heterogeneity challenges and support clinical translation across inflammatory bowel disease and oncology indications
